Adverse drug effects of so-called atypical neuroleptics;Unerwünschte arzneimittelwirkungen unter so genannten atypischen neuroleptika

Psychopharmakotherapie

Volumn 14, Issue 6, 2007, Pages 247-252

  Worek, Franz ^a   Weber, Karina ^a   Haen, Ekkehard ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Adverse drug effects; Atypical neuroleptics; Dose dependence

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADVERSE OUTCOME; AKATHISIA; ARTICLE; BRAIN DYSFUNCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSKINESIA; EDEMA; EMBOLISM; EXTRAPYRAMIDAL SYNDROME; FEVER; GALACTORRHEA; GRAND MAL SEIZURE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MONOTHERAPY; MYALGIA; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OUTPATIENT; PARKINSONISM; PATIENT ASSESSMENT; RASH; SIDE EFFECT; URINE INCONTINENCE; WEIGHT GAIN;

EID: 36549088195     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Baumann P, Hiemke C, Ulrich S, Eckermann G, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:243-65.
2. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172:1703-11.
3. Haen E. AGATE: Qualitätssicherung in der Psychopharmakotherapie. Neurotransmitter 2004;15:34-43.
4. Haen E. Bedeutung der klinisch-pharmakologischen Befundung von Wirkstoffkonzentrationsmessungen zur Therapieleitung. Psychopharmakotherapie 2005;12:138-43.
5. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.